Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
For full access to this article login to GEN Select now.
Necessary Liaisons: CROs Gain Clout & Responsibility
Clinical research organizations are forging more strategic and integrated deals.
- Clinical research organizations (CROs) have never had greater clout. As drug sponsors raced to shed fixed costs while simultaneously struggling to replenish anemic pipelines, CROs stepped in to shoulder more of the development workload. Business boomed (even if profits sometimes haven’t) and CROs grew steadily in size and ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.